Abstract #1119
Multimodality Imaging End-Points on mTOR and HSP Inhibition in Pancreatic Cancer: A Pre-Clinical PET/MRI/MRS Study
Justin Y Lee 1 , Lora A Wilson 2 , Jerri L Choi 3 , Kendra M Huber 4 , Andrea L Merz 4 , Katerina J Kechris 5 , Colin D Weekes 2 , and Natalie J Serkova 4,6
1
Department of Anesthesiology, University of
Colorado Anschutz Medical Campus, Aurora, CO, United
States,
2
Department
of Oncology, University of Colorado Anschutz Medical
Campus, CO, United States,
3
University
of Colorado Anschutz Medical Campus, CO, United States,
4
Department
of Anesthesiology, University of Colorado Anschutz
Medical Campus, CO, United States,
5
Department
of Biostatics and Informatics, University of Colorado
Anschutz Medical Campus, CO, United States,
6
Department
of Radiology, University of Colorado Anschutz Medical
Campus, CO, United States
There is an urgent need to develop novel signal
transduction pathway inhibitor strategies to treat
pancreatic cancer. This project utilizes a combination
of the mTOR inhibitor Everolimus and the HSP-90
inhibitor Ganetepsib with the goal of establishing
metabolic (FDG-PET and 1H-MRS), morphological (DWI), and
anatomical (MRI) end-points to monitor response in mouse
pancreatic adenocarcinoma xenografts. Combination
treatment resulted in decreased tumor growth,
cellularity, and metabolic activity. Our results provide
the first evidence of proliferation and metabolic
response by functional multiparametric imaging and FDG-PET,
DWI and 1H-MRS and identify them as potential biomarkers
in clinical trials.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
